Emergent's cash, Cangene's assets build one company for growth
This article was originally published in Scrip
Executive Summary
Emergent BioSolutions and Cangene both are focused on biodefense and bioscience products, but they aim to be stronger together than they are separately through Emergent's $222m acquisition of its Canadian counterpart.